BRIEF published on 09/24/2024 at 23:05, 1 year 7 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 7 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 7 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 7 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 8 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 8 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 8 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 8 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 8 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 8 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 05/04/2026 at 10:30, 1 hour 29 minutes ago Storm Exploration Plans Drill Program to Test VMS Target at Gold Standard
Published on 05/04/2026 at 01:40, 10 hours 19 minutes ago New Head of Corporate Affairs and Sustainability
Published on 05/02/2026 at 21:00, 1 day 14 hours ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 2 days 10 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 2 days 11 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/04/2026 at 11:39, 20 minutes ago swissnet Group sichert sich bedeutenden Hospitality-Netzwerkinfrastrukturauftrag in Dubai
Published on 05/04/2026 at 11:16, 42 minutes ago EQS-Adhoc: Basler AG reports preliminary financial results for the first quarter of 2026: Very strong start to the year; company raises forecast for 2026
Published on 05/04/2026 at 11:00, 58 minutes ago Vossloh to equip first high-speed rail line in the USA
Published on 05/04/2026 at 10:00, 1 hour 58 minutes ago Original-Research: UmweltBank AG (von GBC AG): BUY
Published on 05/04/2026 at 09:51, 2 hours 7 minutes ago GUILLEMOT CORPORATION: Weekly report share buyback From April 27th 2026 to May 1st 2026
Published on 05/04/2026 at 08:45, 3 hours 14 minutes ago Air Liquide divests its biogas production activities in four countries
Published on 04/30/2026 at 20:00, 3 days 15 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 3 days 16 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 3 days 16 hours ago Capital increase through exercise of subscription rights
